Hormone levels following surgical and medical castration: defining optimal androgen suppression.

Author: Michael T SCHWEIZER ¹ ; Michael L HANCOCK ² ; Robert H GETZENBERG ³ ; Evan Y YU ¹
Author Information

1. Division of Oncology, Department of Medicine, University of Washington, Seattle, WA 98116, USA.
2. Division of Oncology, Department of Medicine, University of Washington, Seattle, WA 98116, USA Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98116, USA Veru Healthcare, Miami, FL 33137, USA.
3. Veru Healthcare, Miami, FL 33137, USA.
Publication Type:Randomized Controlled Trial
MeSH: Aged; Aged, 80 and over; Androgen Antagonists/pharmacology*; Androgens/blood*; Cohort Studies; Gonadotropin-Releasing Hormone/antagonists & inhibitors*; Hormones/blood*; Humans; Luteinizing Hormone/blood*; Male; Middle Aged; Orchiectomy; Prostatic Neoplasms/surgery*; Toremifene/therapeutic use*
From: Asian Journal of Andrology 2018;20(4):405-406
CountryChina
Language:English